Considering the absence of other specific strategies or drugs for patients with stroke, modulating the quantity and function of FoxP3+CD25+CD4+ Tregs may be potential, novel avenues for developing new therapeutics that improve neurological outcomes after stroke. This evidence concerns the gene CD4 and stroke disorder.